Coatue Management Adds $34M in Novavax, Inc. ($NVAX)
Key Points
- Wall Street's consensus rating on $NVAX is Buy and an average price target of $14.11.
- $NVAX last traded around $8.88.
Coatue Management acquired a new position in Novavax, Inc. ($NVAX), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,836,986 shares of Novavax, Inc.. Coatue Management's holdings in Novavax, Inc. were worth $34.07 million as of its most recent filing.
Novavax, Inc. ($NVAX) Stock
Novavax, Inc. Earnings
Analysts Set New Price Targets
About Novavax, Inc.
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.